2-[4-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenoxy]-benzonitrile | 262430-83-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenoxy]-benzonitrile
• 英文别名: 2-[4-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzonitrile
• CAS: 262430-83-1
• 化学式: C₂₂H₁₉N₅O
• 分子量: 369.426
• InChiKey: VKCVHBODVYGOIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  89.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[4-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenoxy]-benzonitrile 在 氢氧化钾 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-[4-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenoxy]-benzoic acid
  参考文献：
  名称：

  Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck II

  摘要：

  Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are novel, potent and selective inhibitors of lck in vitro. Exploration of C-6 position of the pyrrolo[2,3-d]pyrimidine and the terminal phenyl group structure-activity relationship (SAR) is detailed. Compound 1 is orally active in animal models. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00442-x
• 作为产物：
  描述：

  4-amino-7-isopropyl-5-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidine 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-[4-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenoxy]-benzonitrile
  参考文献：
  名称：

  Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck II

  摘要：

  Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are novel, potent and selective inhibitors of lck in vitro. Exploration of C-6 position of the pyrrolo[2,3-d]pyrimidine and the terminal phenyl group structure-activity relationship (SAR) is detailed. Compound 1 is orally active in animal models. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00442-x

文献信息

• 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS
  申请人：——

  公开号：US20030187001A1

  公开（公告）日：2003-10-02

  Chemical compounds having structural formula I 1 and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperpro;iferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

  具有结构式I1的化合物及其生理上可接受的盐是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞高增殖是因素的疾病状态。这些化合物可用于治疗癌症、高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• Method of treating transplant rejection
  申请人：Waegell Wendy

  公开号：US20050008640A1

  公开（公告）日：2005-01-13

  This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.

  本发明涉及一种治疗移植排斥的方法，包括向患者施用一种药物组合物，该药物组合物包括lck抑制剂和钙调蛋白酶抑制剂或免疫抑制剂。
• US7863444B2
  申请人：——

  公开号：US7863444B2

  公开（公告）日：2011-01-04
• [EN] METHOD OF TREATING TRANSPLANT REJECTION<br/>[FR] PROCEDE SERVANT A TRAITER LE REJET D'UN TRANSPLANT
  申请人：ABBOTT LAB

  公开号：WO2004100868A2

  公开（公告）日：2004-11-25

  This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.
• Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck II
  作者：Andrew F Burchat、David J Calderwood、Gavin C Hirst、Nicholas J Holman、David N Johnston、Rainer Munschauer、Paul Rafferty、Gerald B Tometzki

  DOI：10.1016/s0960-894x(00)00442-x

  日期：2000.10

  Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are novel, potent and selective inhibitors of lck in vitro. Exploration of C-6 position of the pyrrolo[2,3-d]pyrimidine and the terminal phenyl group structure-activity relationship (SAR) is detailed. Compound 1 is orally active in animal models. (C) 2000 Elsevier Science Ltd. All rights reserved.